Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01926990 | Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma | completed | — | 19 | Stanford UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT00112840 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01399918 | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT05168436 | A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | completed | — | 105 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 23, 2021 | clinicaltrials |
| NCT04342286 | To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer | completed | — | 20 | Chinese University of Hong KongOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT03916458 | REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA(ATILA) | completed | — | 62 | PfizerINDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01472081 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | completed | Phase 1 | 194 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 2, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04353765 | Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors(US NIS Cabo) | completed | — | 247 | IpsenINDUSTRY | 1 | Nov 17, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01358721 | Phase I Biomarker Study (BMS-936558) | completed | Phase 1 | 119 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 28, 2021 | clinicaltrials |
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen(NIVOREN) | completed | Phase 2 | 730 | UNICANCEROTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03900364 | a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy | completed | N/A | 30 | Salzburger LandesklinikenOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05042089 | Predictive Imaging Features in Renal Cell Carcinoma | completed | — | 92 | Ankara Yildirim Beyazıt UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04377113 | Cellular Immunity and Renal Cell Cancer | completed | — | 60 | Clinical Hospital Center RijekaOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT01392183 | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | completed | Phase 2 | 35 | TakedaINDUSTRY | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03525834 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02599779 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients(OZM-065) | completed | Phase 2 | 4 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT03748901 | PD-L1 Expression in Japanese Renal Cell Carcinoma Patients | completed | — | 830 | Chugai PharmaceuticalINDUSTRY | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04496089 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC(ZIRDAC-JP) | completed | Phase 1 | 6 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01896271 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00369564 | Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer | completed | Phase 3 | 250 | University of South FloridaOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01826877 | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer | completed | Phase 1 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01024920 | Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 5 | Jul 19, 2021 | clinicaltrials |
| NCT02989714 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | completed | Phase 1 / Phase 2 | 13 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03494816 | Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion(NAXIVA) | completed | Phase 2 | 24 | Scottish Clinical Trials Research UnitOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04933604 | LPN in Patients With High-complex Renal Tumors | completed | — | 78 | Samsun Liv HospitalOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT00414765 | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | completed | Phase 4 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT04309617 | Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy | completed | — | 618 | PfizerINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT03354884 | caBozantinib in cOllectiNg ductS Renal Cell cArcInoma(BONSAI) | completed | Phase 2 | 23 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT04873180 | Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma | completed | — | 40 | Sohag UniversityOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT03463681 | A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma(BREAKPOINT) | completed | Phase 2 | 49 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT02127710 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | completed | Phase 2 | 111 | AstraZenecaINDUSTRY | 4 | Apr 19, 2021 | clinicaltrials |
| NCT04162834 | Effect of Papaverine on Renal Artery Blood Flow Volume | completed | Phase 4 | 96 | Asan Medical CenterOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT00121251 | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03065179 | SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients(RADVAX) | completed | Phase 2 | 29 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02537743 | Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma(PROKidney) | completed | — | 98 | iOMEDICO AGINDUSTRY | 1 | Mar 25, 2021 | clinicaltrials |
| NCT02363751 | Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)(BEVABEL) | completed | Phase 2 | 36 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 2, 2022source: clinicaltrials